Previous close | 2.4900 |
Open | 2.4900 |
Bid | 2.5400 x 100 |
Ask | 2.6100 x 400 |
Day's range | 2.4800 - 2.6000 |
52-week range | 1.6900 - 3.1500 |
Volume | |
Avg. volume | 961,668 |
Market cap | 466.679M |
Beta (5Y monthly) | 2.04 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4400 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.40 |
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL: Barclays 26th Annual Global Healthcare Con
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders are probably feeling a little disappointed, since its shares...
Today is shaping up negative for Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders, with the analysts...